The Center for
Business Intelligence (CBI) will be holding its 4th Summit on Biosimilars and
Follow-on Biologics on March 18-19, 2010 in Washington, DC.  At the Summit, CBI's faculty will offer
presentations on the following topics:

• Understand the developing biosimilars
framework in the United States and European Union;
• Biologics similarity — How will this
be defined? (panel discussion);
• FDA update on the scientific issues
associated with evaluating FOB submissions;
• Update on healthcare reform policy
and implications for bio/pharma;
• From the Hill — Biosimilars
legislative perspectives (panel discussion);
• European monoclonal antibody draft
guidance — What will this mean for the U.S.?
• Update on reimbursement systems,
benefit design implications and clinical/patient safety considerations for
biosimilars;
• Understand provider perspectives on
the use of biosimilars;
• Lessons learned from Hospira's EU
biosimilar experiences;
• Partnering with biobetters to
facilitate approval and increase product update;
• The biosimilars business model —
Opportunities and pitfalls;
• Follow-on perspective; and
• Innovator perspective.

A complete agenda
for the Summit on Biosimilars and Follow-on Biologics can be found here (Day
One)
and here (Day Two).  A brochure for this conference can be
requested here.

The registration
fee for the conference is $2,095. 
Attendees registering on or before January 22, 2010 will receive a $400
discount off the registration fee, and attendees registering a group of three
individuals will receive a fourth registration for free.  Those interested in registering for the
conference can do so here,
by calling 1-800-817-8601, or by e-mail at cbireg@cbinet.com.

Patent Docs is a media partner of CBI's Summit on Biosimilars and Follow-on
Biologics.